<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PIPERACILLIN SODIUM<img border="0" src="../images/pr.gif"/></span><br/>(pi-per'a-sill-in)<br/><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span>; <span class="classification">antipseudomonal penicillin</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 g, 3 g, 4 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Action is similar to that of other penicillins. Interference with bacterial cell wall synthesis promotes loss of membrane
         integrity and leads to death of the organism.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Extended-spectrum parenteral penicillin with antibiotic activity against most gram-negative and many gram-positive anaerobic
         and aerobic organisms including members of <i>Clostridium, Bacteroides, Klebsiella, Enterobacter, Pseudomonas, Proteus,</i> and <i>Serratia</i> species and the anaerobic and aerobic cocci. Less active than penicillin G against <i>Pneumococci</i> and group A <i>Streptococci</i> but comparable to ampicillin against <i>Enterococci</i>. Penicillinase-producing <i>Staphylococci</i> are resistant to piperacillin.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Susceptible organisms that cause gynecologic, skin and skin structure, gonococcal, and streptococcal infections; lower respiratory
         tract, intraabdominal, and bone and joint infections; septicemia, urinary tract infections. Also prophylactically prior to
         and during surgery and as empiric antiinfective therapy in granulocytopenic patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to penicillins, cephalosporins, or other drugs; pregnancy (category B); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver and kidney dysfunction; hypersensitivity to cephalosporins.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Uncomplicated Urinary Tract Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 816 g/d divided q68h<br/><br/><span class="indicationtitle">Mild to Moderate Infections</span><br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 200300 mg/kg/d divided q46h (max: 24 g/d)<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 150200 mg/kg/d divided q68h<br/><br/><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 4 g q6h (150200 mg/kg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">IV</span> 24 g q68h <span class="rdroute">IM</span> 12 g q812h<br/><br/><span class="indicationtitle">Life-threatening Infection, <i>Pseudomonas</i> Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 3 g q4h (max: 24 g/d)<br/><br/><span class="indicationtitle">Uncomplicated Gonococcal Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 2 g with 1 g probenecid given 30 min before piperacillin<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Patients undergoing hemodialysis usually receive a maximum dosage of 2 g piperacillin q8h and an additional 1 g dose after
         each dialysis period. Doses and frequency are usually modified if creatinine clearance is <span class="adminroutetype">Intramuscular</span><br/></p><ul>
<li>Limit IM injections to 2 g/site. Use the gluteal muscle, preferably. Use deltoid muscle only if well developed.</li>
<li>Diluents for reconstitution include sterile or bacteriostatic water for injection, bacteriostatic NaCl injection, and sterile
            lidocaine HCl injection 0.51.0% without epinephrine for IM. When reconstituted, solution contains 1 g/2.5 mL.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion for administration to neonates, infants, or children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> (Not preferred): Reconstitute by diluting 1 g with 5 mL sterile water or NS for injection. Shake well until dissolved.  <span class="methodtype">Intermittent:</span> (Preferred): Further dilute with 50100 mL NS or D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>  (Not preferred): Give over 35 min. Avoid rapid injection.  <span class="methodtype">Intermittent:</span> (Preferred): Give over 30 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">aminoglycosides</span>. <span class="incompattype">Y-site:</span>
<span class="classification">aminoglycosides</span>, <b>amiodarone, amphotericin B cholesteryl complex,</b>
<b>cisatracurium,</b>
<b>filgrastim,</b>
<b>fluconazole,</b>
<b>gemcitabine,</b>
<b>ondansetron,</b>
<b>sargramostim,</b>
<b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Coughing, sneezing, feeling of uneasiness; <span class="speceff-life">systemic anaphylaxis</span>, fever, widespread increase in capillary permeability and vasodilation with <span class="speceff-life">resulting edema (mouth, tongue, pharynx, larynx), laryngospasm</span>, malaise, serum sickness (fever, malaise, pruritus, urticaria, lymphadenopathy, arthralgia, angioedema of face and extremities,
      neuritis prostration, eosinophilia), SLE-like syndrome, Injection site reactions (pain, inflammation, abscess, phlebitis),
      superinfections (especially with <span class="speceff-common">Candida</span> and gram-negative bacteria), neuromuscular irritability (twitching, lethargy, confusion, stupor, hyperreflexia, multifocal
      myoclonus, localized or generalized seizures, <span class="speceff-life">coma</span>). <span class="typehead">CV:</span> Hypotension, <span class="speceff-life">circulatory collapse</span>, cardiac arrhythmias, <span class="speceff-life">cardiac arrest</span>. <span class="typehead">GI:</span> Vomiting, diarrhea, severe abdominal cramps, nausea, epigastric distress, diarrhea, flatulence, dark discoloration of tongue,
      sore mouth or tongue. <span class="typehead">Urogenital:</span> Interstitial nephritis, Loeffler's syndrome, vasculitis. <span class="typehead">Hematologic:</span> Hemolytic anemia, thrombocytopenia. <span class="typehead">Metabolic:</span> Hyperkalemia (penicillin G potassium); hypokalemia, alkalosis, hypernatremia, CHF (penicillin G sodium). <span class="typehead">Respiratory:</span> Bronchospasm, asthma. <span class="typehead">Skin:</span> Itchy palms or axilla, pruritus, <span class="speceff-common">urticaria</span>, flushed skin, <span class="speceff-common">delayed skin rashes</span> ranging from urticaria to exfoliative dermatitis, Stevens-Johnson syndrome, fixed-drug eruptions, contact dermatitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase risk of bleeding with <span class="classification">anticoagulants</span>; <b>probenecid</b> decreases elimination of piperacillin. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 45 min IM; 5 min IV. <span class="typehead">Distribution:</span>  Widely distributed with highest concentrations in urine and bile; adequate CSF penetration with inflamed meninges; crosses
      placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Slightly metabolized in liver. <span class="typehead">Elimination:</span> Primarily excreted in urine, partly in bile. <span class="typehead">Half-Life:</span> 0.61.35 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain history of hypersensitivity to penicillins, cephalosporins, or other drugs prior to administration.</li>
<li>Lab tests: C&amp;S prior to first dose of the drug; start drug pending results. Periodic CBC with differential, platelet count,
            Hgb and Hct, and serum electrolytes.
         </li>
<li>Monitor for hypersensitivity response; discontinue drug and notify physician if allergic response noted.</li>
<li>Lab tests: Periodic CBC with differential, platelet count, Hgb and Hct, and serum electrolytes.</li>
<li>Monitor for hemorrhagic manifestations because high doses may induce coagulation abnormalities.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report significant, unexplained diarrhea.</li>
<li>Withhold drug and report to physician if signs of an allergic reaction develop (e.g., itching, rash, hives).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>